Novel avenues for Clostridium difficile infection drug discovery

Expert Opinion on Drug Discovery

Volumn 8, Issue 4, 2013, Pages 459-477

  Zucca, Mario ^a   Scutera, Sara ^a   Savoia, Dianella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibiotics; Antimicrobial peptides; Clostridium difficile; Fecal therapy; Phage therapy; Probiotics; Toxins; Virulence factors

Indexed keywords

ACT 179811; ALPHA DEFENSIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIOCIN; CADAZOLID; CB 183,315; LANTIBIOTIC; LFF 571; MBX 500; NVB 302; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; RAMOPLANIN; REP 3123; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIOPHAGE; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BINDING SITE; CHEMICAL STRUCTURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; CROSS RESISTANCE; DRUG HALF LIFE; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPEN READING FRAME; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUORUM SENSING; REVIEW; RNA BINDING;

ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG DISCOVERY; FECES; HUMANS; METAGENOME;

EID: 84875407653     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.770466     Document Type: Review

References (159)

1. Larson HE, Price AB, Honour P, et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978;1:1063-6
2. Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 2009;33(S1):52-8
3. Bartlett JG. Clostridium difficile infection: historic review. Anaerobe 2009;15:227-9
4. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-72
5. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. CID 2012;55(Suppl 2):S65-70
6. Wiegand PN, Nathwani D, Wilcox MH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1-14
7. Bartlett JG. Clostridium difficile: progress and challenges. Ann NY Acad Sci 2010;1213:62-9
8. Cartman ST, Heap JT, Kuehne SA, et al. The emergence of 'hypervirulence' in Clostridium difficile. Int J Med Microbiol 2010;300:387-95
9. Deneve C, Janoira C, Poilane I, et al. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009;33(S1):S24-8
10. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70
11. Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med 1989;110:255-7
12. Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001;98:5844-9
13. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40
14. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 2012;20:21-9
15. Bartlett JG. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 2009;11:21-8
16. Huang H, Weintraub A, Fang H, et al. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009;34:516-22
17. Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012;55(Suppl 2):S71-6
18. Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 2012;34:1-13
19. McFarland LV. Emerging therapies for Clostridium difficile infections. Exp Opin Emerg Drugs 2011;16:425-39
20. Mascio CTM, Mortin LI, Howland KT, et al. In vitro and in vivo characterization of CB-183, 315, a novel lipopeptide antibiotic for the treatment of Clostridium difficile. Antimicrob Agents Chemother 2012;56:5023-30
21. Citron DM, Tyrrell KL, Merriam V, et al. In Vitro activities of CB-183, 315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 2012;56:1613-15
22. Freeman J, Baines SD, Jabes D, et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56:717-25
23. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microbiol Ecol 1998;35:180-7
24. Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol 2011;14:564-9
25. Available from: http://www. nanotherapeutics.com/products-pipeline- ramoplanin.php [Last accessed 2 August 2012]
26. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54(Suppl 3):S214-19
27. Chilton CH, Freeman J, Crowther GS, et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012;67:2434-7
28. Van Bambeke F, Carryn S, Seral C, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004;48:2853-60
29. Chritchley IA, Green LS, Young CL, et al. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009;63:954-63
30. Citron DM, Warren YA, Tyrrell KL, et al. Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009;63:972-6
31. Ochsner UA, Bell SJ, O'Leary AL, et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009;63:964-71
32. Butler MM, LaMarr WA, Foster KA, et al. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother 2007;51:119-27
33. Butler MM, Shinabarger DL, Citron DM, et al. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 2012;56:4786-92
34. LaMarche MJ, Leeds JA, Amaral A, et al. Discovery of LFF571: An investigational agent for Clostridium difficile infection. J Med Chem 2012;55:2376-87
35. Available from: clinicaltrials.gov [Last access 16 January 2013]
36. Available from: www.actelion.com [Last accessed 8 January 2013]
37. Baldoni D, Gutierrez M, Dingemanse J, et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: safety, tolerability, and pharmacokinetics in healthy subjects following single and multiple oral doses. Poster (A-1273), Session 162, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9-12 September 2012; San Francisco
38. Chopra I. The magainins: antimicrobial peptides with potential for topical application. J Antimicrob Chemother 1993;32:351-3
39. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010;1:440-64
40. Harris F, Dennison SR, Phoenix DA. Anionic antimicrobial peptides from eukaryotic organisms. Curr Protein Pept Sci 2009;10:585-606
41. Anaya-Lopez JL, Lopez-Meza JE, Ochoa-Zarzosa A. Bacterial resistance to cationic antimicrobial peptides. Crit Rev Microbiol 2012;doi:10.3109/1040841X. 2012.699025
42. Lloyd DH. Alternatives to conventional antimicrobial drugs: a review of future prospects. Vet Dermatol 2012;23:299-304
43. Hassan M, Kjos M, Nes IF, et al. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol 2012;113:723-36
44. Chatterjee C, Paul M, Xie L, et al. Biosynthesis and mode of action of lantibiotics. Chem Rev 2005;105:633-84
45. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005;3:777-88
46. Ross AC, Vederas JC. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J Antibiot 2011;64:27-34
47. Johnson AP. New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opin Ther Patents 2010;20:1389-99
48. Crowther GS, Baines SD, Todhunter SL, et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013;68:168-76
49. Available from: http://www.wellcome.ac. uk/News/2012/News/WTVM056086. htm [Last accessed 11 January 2013]
50. Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 1984;44:141-4
51. Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 2009;33:70-4
52. Available from: http://www.oragenics. com/?q=lantibiotics [Last accessed 22 August 2012]
53. Corr SC, Li Y, Riedel CU, et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. PNAS 2007;104:7617-21
54. Ryan MP, Rea MC, Hill C, et al. An Application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 1996;62:612-19
55. Rea MC, Clayton E, O'Connor PM. Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 2007;56:940-6
56. Rea MC, Dobson A, O'Sullivan O, et al. Effect of broad-and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. PNAS 2011;108(Suppl 1):4639-44
57. Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. PNAS 2010;107:9352-7
58. Murphy K, O'Sullivan O, Rea MC, et al. Genome mining for radical SAM protein determinants reveals multiple sactibiotic-like gene clusters. PLoS One 2011;6:e20852
59. Sofia HJ, Chen G, Hetzler BG, et al. Radical SAM, a novel protein superfamily linking unresolved steps in familiar biosynthetic pathways with radical mechanisms: functional characterization using new analysis and information visualization methods. Nucleic Acids Res 2001;29:1097-106
60. Zucca M, Scutera S, Savoia D. Antimicrobial peptides: new frontiers in the therapy of infections. In: Drug development. A case study based insight into modern strategies. Rundfeldt, InTech; Croatia: 2011. p. 123-62
61. Ramasundara M, Leach ST, Lemberg DA, et al. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroent Hepatol 2009;24:202-8
62. Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol 2012;12:1-6
63. Giesemann T, Guttenberg G, Aktories K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008;134:2049-58
64. Chen H, Xu Z, Peng L, et al. Recent advances in the research and development of human defensins. Peptides 2006;27:931-40
65. Wencker M, Brantly ML. Cytotoxic concentrations of alpha-defensins in the lungs of individuals with alpha 1-antitrypsin deficiency and moderate to severe lung disease. Cytokine 2005;32:1-6
66. Hwang JS, Lee J, Kim Y-J, et al. Isolation and characterization of a defensin-like peptide (coprisin) from the dung beetle, Copris tripartitus. Int J Pept 2009;2009:doi:pii 136284. 10.1155/2009/136284; Epub 2009 Oct 22
67. Scott RW, DeGrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol 2008;19:620-7
68. Kang JK, Hwang JS, Nam HJ, et al. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. J Antimicrob Agents Chemother 2011;55:4850-7
69. McBride SM, Sonenshein AL. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 2011;79:167-76
70. Chen AGY, Sudarsan N, Breaker RB. Mechanism for gene control by a natural allosteric group I ribozyme. RNA 2011;17:1967-72
71. Guan L, Disney MD. Recent advances in developing small molecules targeting RNA. ACS Chem Biol 2012;7:73-86
72. Lee ER, Baker JR, Weinberg Z, et al. An allosteric self-splicing ribozyme triggered by a bacterial second messenger. Science 2010;329:845-8
73. Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nat Biotechnol 2006;24:1558-64
74. Deigan KE, Ferrè-D'Amarè AR. Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Accounts Chem Res 2011;44:1329-38
75. Ster C, Allard M, Boulanger S, et al. Experimental treatment of Staphylococcus aureus bovine intramammary infection using a guanine riboswitch ligand analog. J Dairy Sci 2013;96:1-9.Available from: http://dx.doi.org/10. 3168/jds.2012-5890
76. Purcell EB, McKee RW, McBride SM, et al. Cyclic diguanylate inversely regulates motility and aggregation in Clostridium difficile. J Bacteriol 2012;194:3307-16
77. Ethapa T, Leuzzi R, Ng YK, et al. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 2013;195:545-55
78. Sudarsan N, Lee ER, Weinberg Z, et al. Riboswitches in Eubacteria sense the second messenger cyclic di-GMP. Science 2008;321:411-13
79. Bordeleau E, Fortier LC, Malouin F, et al. c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS Genet 2011;7:e1002039
80. Aubry A, Hussack G, Chen W, et al. Modulation of toxin production by the flagellar regulon in Clostridium difficile. Infect Immun 2012;80:3521-32
81. Donelli G, Vuotto C, Cardines R, et al. Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microbiol 2012;65:318-25
82. Reynolds CB, Emerson JE, de la Riva L, et al. The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog 2011;7:1-14
83. Furukawa K, Gu H, Sudarsan N, et al. Identification of ligand analogues that control c-di-GMP riboswitches. ACS Chem Biol 2012;7:1436-43
84. Martin CA, Hoven AD, Cook AM. Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing. Eur J Clin Microbiol Infect Dis 2008;27:635-42
85. Pereira CS, Thompson JA, Xavier KB. AI-2-mediated signalling in bacteria. FEMS Microbiol Rev 2012;doi: 10.1111/j.1574-6976.2012.00345
86. Carter GP, Purdy D, Williams P, et al. Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. J Med Microbiol 2005;54:119-27
87. Lee ASY, Song KP. LuxS/autoinducer-2 quorum sensing molecule regulates treanscriptional virulence gene expression in Clostridium difficile. Biochem Biophys Res Commun 2005;335:659-66
88. Kaufmann GF, Sartorio R, Lee S-H, et al. Revisiting quorum sensing: discovery of additional chemical and biological functions for3-oxo-N- acylhomoserine lactones. PNAS 2005;102:309-14
89. Ueda C, Tateda K, Horikawa M, et al. Anti-Clostridium difficile potential of tetramic acid derivatives from Pseudomonas aeruginosa quorum-sensing autoinducers. Antimicrob Agents Chemother 2010;54:683-8
90. d'Herelle F. Sur un microbe invisible antagoniste des bacillus dysentérique. C R Acad Sci Paris 1917;165:373-5
91. Brüssow H. What is needed for phage therapy to become a reality in Western medicine? Virology 2012;434:138-42
92. Abedon ST, Kuhl SJ, Blasdel BG, et al. Phage treatment of human infections. Bacteriophage 2011;1:66-85
93. Available from: http://www.who.int/dg/speeches/2011/WHD-20110407/en/ index/html
94. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011;9:894-6
95. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today 2005;10:807-9
96. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009;4:e4944
97. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009;18:237-43
98. Wright A, Hawkins CH, Anggard EE, et al. A controlled clinical trial of a therapeutical bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009;34:349-57
99. Hawkins C, Harper D, Burch D, et al. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 2010;146:309-13
100. Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012. In press Available from: http://dx. doi.org/10.1016/j.virol.2012.09.002
101. Brüssow H. Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining? MBio 2012;3:e00061-12
102. Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent P. aeruginosa lung infections. J Infect Dis 2010;201:1096-104
103. Alemayehu D, Casey PG, McAuliffe O, et al. Bacteriophages fMR299-2 and fNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012;3:e00029-12
104. Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res 2012;83:123-41
105. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect 2008;38:426-30
106. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res 2012;83:73-121
107. Chanisvili N. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 2012;83:3-40
108. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011;1:111-14
109. Verbeken G, Pirnay JP, De Vos D, et al. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 2012;60:161-72
110. Parracho HMRT, Burrowes BH, Enright MC, et al. The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genet Med 2012;6:279-86
111. Ramesh V, Fralich JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 1999;5:269-78
112. Meader E, Mayer MJ, Gasson MJ, et al. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 2010;16:549-54
113. Available from: www.novolytics.co.uk [Last accessed 31 August 2012]
114. Hagens S, Bläsi U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003;37:318-23
115. Perry JD, Asir K, Halimi D, et al. Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol 2010;48:3852-8
116. Loessner MJ. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 2005;8:480-7
117. Borysowski J, Weber-Dabrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 2006;231:366-77
118. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram positive pathogens. Int J Med Microbiol 2010;300:357-62
119. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001;294:2170-2
120. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008;11:393-400
121. Mayer MJ, Narbad A, Gasson MJ. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 2008;190:6734-40
122. Mayer MJ, Garefalaki V, Spoerl R. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol 2011;193:5477-86
123. Ciorba MA. A gastroenterologist's guide to probiotics. Clin Gastroenterol Hepatol 2012;9:960-8
124. Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: more drugs, less dietary supplementation. Int J Antimicrob Agents 2012;40:288-96
125. Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl 2):S104-11.discussion S144-51
126. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-9
127. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010.16(11):1661-5.
128. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
129. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41
130. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16:2202-22
131. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009;15:281-4
132. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16:e786-92
133. Cartman ST. Time to consider Clostridium probiotics? Future Microbiol 2011;6:969-71
134. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 1985;19:339-50
135. Merrigan MM, Sambol SP, Johnson S, et al. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009;33:S46-50
136. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
137. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 2003;45:86-90
138. Villano SA, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012;56:5224-9
139. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br J Nut 1998;80:S209-12
140. Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr 1998;80:S197-202
141. Grizard D, Barthomeuf C. Non-digestible oligosaccharides used as prebiotic agents: mode of production and beneficial effects on animal and human health. Reprod Nutr Dev 1999;39:563-88
142. Hopkins MJ, Mcfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003;69:1920-7
143. Euler AR, Mitchell DK, Kline R, et al. Prebiotic effect of fructo-oligosaccharide supplemented term infant formula at two concentrations compared with unsupplemented formula and human milk. J Pediatr Gastroenterol Nutr 2005;40:157-64
144. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010;44:567-70
145. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011;45:S159-67
146. Kassam Z, Hundal R, Marshall JK, et al. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012;172:191-3
147. Jorup-Röonströom C, Häkanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012;47:548-52
148. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficle diarrhoea in six patients. Lancet 1989;1:1156-60
149. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012;8:e1002995
150. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012;4:149-58
151. Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med 2012;13:75-83
152. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
153. Greenberg RN, Marbury TC, Foglia G, et al. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012;30:2245-9
154. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:2202-4
155. Puri AW, Lupardus PJ, Deu E, et al. Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol 2010;17:1201-11
156. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 2008;3:653-9
157. Seal BS. Characterization of bacteriophages virulent for Clostridium perfringens and identification of phage lytic enzymes as alternatives to antibiotics for potential control of the bacterium1. Poult Sci 2013;92:526-33
158. Keen EC. Phage therapy: concept to cure. Front Microbiol 2012;3:238
159. Muniesa M, Hammerl JA, Hertwig S, et al. Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol 2012;78:4065-73